Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Chia C. Portera, Janice M. Walshe, Douglas R. Rosing, +9

Clinical Cancer Research

A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Zev A. Wainberg, Wells A. Messersmith, Parvin F. Peddi, +5

Clinical Colorectal Cancer

Phase 1BOncologyGastrointestinal OncologyMedicineColorectal Cancer +6

Learning and Confirming with Preclinical Studies: Modeling and Simulation in the Discovery of GDC-0917, an Inhibitor of Apoptosis Proteins Antagonist

Harvey Wong, Stephen E. Gould, Nageshwar Budha, +13

Drug Metabolism and Disposition

Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer

Caio M. Rocha Lima, Soley Bayraktar, Aurea M. Flores, +9

Cancer Investigation

Phase Ib StudyDose LevelAdvanced RecurrentOncologyMedicine +10

A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors

Anthony W. Tolcher, Johanna C. Bendell, Kyriakos P. Papadopoulos, +12

Clinical Cancer Research

Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months

Begoña de las Heras, Kamal S. Saini, Frances Boyle, +16

Oncology and Therapy

Phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma.

Anthony W. Tolcher, Kyriakos P. Papadopoulos, Amita Patnaik, +12

Journal of Clinical Oncology

ApoptosisCell DeathPharmacotherapyImmunotherapeuticsRefractory Solid Tumors +14

Evaluation of Lymphangiogenic Factors, Vascular Endothelial Growth Factor D and E-Cadherin in Distinguishing Inflammatory From Locally Advanced Breast Cancer

Paul H. Levine, Chia C. Portera, Heather J. Hoffman, +5

Clinical Breast Cancer

Lymphangiogenic FactorsBreast OncologyAngiogenesisMedicineImmunology +9

Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC).

Saifuddin M. Kasubhai, Johanna C. Bendell, Mark Kozloff, +4

Journal of Clinical Oncology

Disease ProgressionApoptosisPathologyCell DeathMcrc Pts +20

FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer

Bora Lim, Angelique Scicchitano, Cheryl Beachler, +7

Cancer Biology & Therapy

Tumor BiologySurgical OncologyGastrointestinal OncologyMedicinePharmacology +10